ReviewEJHaem2026
Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany.
Review in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH-dependent, making them susceptible to interactions with acid-suppressing agents such as proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs) and antacids. Despite clear warnings, real-world data show frequent co-administration, which may compromise therapeutic efficacy. Methods: This study combines two approaches-(1) a systematic review summarizing the impact of acid suppressants on TKI pharmacokinetics and clinical outcomes, and (2) an analysis of German prescription data from the Insight Health co-prescription database, focusing on TKIs primarily used for CML. Results: Results indicate substantial co-prescription rates involving dasatinib, nilotinib, imatinib, bosutinib and ponatinib, with variations across years and agents. Pharmacokinetic evidence demonstrates that PPIs and H2RAs can significantly reduce systemic TKI exposure, with reported decreases of up to 96% in peak plasma concentration and 88% in overall exposure. These reductions have been associated with poorer clinical outcomes, including decreased survival. Conclusion: The findings highlight the need for improved prescriber awareness, adherence to guidelines and risk mitigation strategies such as therapeutic drug monitoring or alternative dosing. Collaborative efforts between clinicians and regulatory bodies are essential to minimize risks and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.